PMID- 19624787
OWN - NLM
STAT- MEDLINE
DCOM- 20101029
LR  - 20211020
IS  - 1742-1241 (Electronic)
IS  - 1368-5031 (Print)
IS  - 1368-5031 (Linking)
VI  - 63
IP  - 8
DP  - 2009 Aug
TI  - Tolterodine extended release is well tolerated in older subjects.
PG  - 1198-204
LID - 10.1111/j.1742-1241.2009.02108.x [doi]
AB  - OBJECTIVES: To investigate the tolerability of tolterodine extended release (ER) 
      in older subjects with overactive bladder (OAB). METHODS: This was a 
      retrospective analysis of pooled data from five large, randomised, double-blind, 
      placebo-controlled trials. Subjects with OAB symptoms, including urinary 
      frequency and urgency (and nocturia in two studies) with or without urgency 
      urinary incontinence, received qd treatment with tolterodine ER (4 mg) or placebo 
      for 8-12 weeks. Data were stratified post hoc by age group: < 65 (n = 2531), 
      65-74 (n = 1059) and > or = 75 years (n = 573). Tolerability was assessed by 
      evaluating the occurrence of adverse events (AEs). AE occurrences from each study 
      were mapped to the MedDRA coding dictionary of preferred terms. RESULTS: 
      Discontinuation rates were slightly higher among subjects > or = 75 years of age 
      vs. those < 65 years of age; however, this was observed in subjects treated with 
      placebo as well as tolterodine ER. Overall, there were no significant differences 
      in the occurrence of dry mouth, headache, constipation, nausea, urinary tract 
      infection, blurred vision, dry eye, dizziness and micturition disorder in older 
      (65-74 or > or = 75 years) vs. younger (< 65 years) subjects treated with 
      tolterodine ER relative to placebo (treatment x age; all p > 0.1). Dry mouth was 
      the only AE consistently associated with tolterodine ER treatment (< 65 years, 
      17%; 65-74 years, 16%; > or = 75 years, 15%). The occurrence of all other AEs was 
      < or = 5% in most age and treatment cohorts. Most AEs were mild or moderate in 
      all age and treatment cohorts. CONCLUSION: The nature and frequency of AEs 
      associated with tolterodine ER treatment were similar across age groups in 
      subjects with OAB, suggesting that tolterodine ER was not associated with an 
      increased risk of AEs in older vs. younger subjects and, thus, is a suitable 
      first-line pharmacotherapy treatment for OAB in this population.
FAU - Griebling, T L
AU  - Griebling TL
AD  - Department of Urology and The Landon Center on Aging, University of Kansas, 3901 
      Rainbow Boulevard, Kansas City, KS 66160, USA. tgriebling@kumc.edu
FAU - Kraus, S R
AU  - Kraus SR
FAU - Richter, H E
AU  - Richter HE
FAU - Glasser, D B
AU  - Glasser DB
FAU - Carlsson, M
AU  - Carlsson M
LA  - eng
GR  - U01 DK058234/DK/NIDDK NIH HHS/United States
GR  - U01 DK058234-09/DK/NIDDK NIH HHS/United States
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PL  - India
TA  - Int J Clin Pract
JT  - International journal of clinical practice
JID - 9712381
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Cresols)
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Muscarinic Antagonists)
RN  - 33RU150WUN (Phenylpropanolamine)
RN  - 5T619TQR3R (Tolterodine Tartrate)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Benzhydryl Compounds/*administration & dosage/adverse effects
MH  - Cresols/*administration & dosage/adverse effects
MH  - Delayed-Action Preparations
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Muscarinic Antagonists/*administration & dosage/adverse effects
MH  - Phenylpropanolamine/*administration & dosage/adverse effects
MH  - Randomized Controlled Trials as Topic
MH  - Retrospective Studies
MH  - Tolterodine Tartrate
MH  - Treatment Outcome
MH  - Urinary Bladder, Overactive/*drug therapy
PMC - PMC2737749
EDAT- 2009/07/25 09:00
MHDA- 2010/10/30 06:00
CRDT- 2009/07/24 09:00
PHST- 2009/07/24 09:00 [entrez]
PHST- 2009/07/25 09:00 [pubmed]
PHST- 2010/10/30 06:00 [medline]
AID - IJCP2108 [pii]
AID - 10.1111/j.1742-1241.2009.02108.x [doi]
PST - ppublish
SO  - Int J Clin Pract. 2009 Aug;63(8):1198-204. doi: 10.1111/j.1742-1241.2009.02108.x.